Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 8/20 | 0.62 |
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flubendazole SCHEMBL8005889 | 0.94 | KDR (0.76) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL29409278 | 0.94 | KDR (0.82) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL167185 | 0.94 | KDR (0.82) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL22321861 | 0.93 | KDR (0.80) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Flubendazole SCHEMBL28005737 | 0.90 | KDR (0.76) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Mebendazole SCHEMBL15860 | 0.89 | ABL1 (0.82) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Mebendazole SCHEMBL29409261 | 0.89 | ABL1 (0.82) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Mebendazole SCHEMBL3429179 | 0.89 | ABL1 (0.82) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Mebendazole SCHEMBL21051203 | 0.88 | ABL1 (0.80) | KDRMAPK1ADORA3PTGS1RXFP1 | |
| Mebendazole SCHEMBL21051200 | 0.88 | ABL1 (0.80) | KDRMAPK1ADORA3PTGS1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432451-A2 | COMPOSITIONS FOR THE TREATMENT OF METASTATIC CANCER AND METHODS OF USE THEREOF | Children's Medical Center Corporation (US) | 2012-03-28 | — | — | EP | claimed |
| US-20120064008-A1 | COMPOSITIONS FOR THE TREATMENT OF METASTATIC CANCER AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-03-15 | — | — | US | claimed |
| WO-2010135534-A2 | COMPOSITIONS FOR THE TREATMENT OF METASTATIC CANCER AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-11-25 | — | — | WO | claimed |
| EP-2432451-A2 | COMPOSITIONS FOR THE TREATMENT OF METASTATIC CANCER AND METHODS OF USE THEREOF | Children's Medical Center Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120064008-A1 | COMPOSITIONS FOR THE TREATMENT OF METASTATIC CANCER AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-03-15 | — | — | US | disclosed |
| WO-2010135534-A2 | COMPOSITIONS FOR THE TREATMENT OF METASTATIC CANCER AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064008-A1 | COMPOSITIONS FOR THE TREATMENT OF METASTATIC CANCER AND METHODS OF USE THEREOF | MKI67, ACP3, PAICS | KDR 3035/4885MAPK1 2879/4885ADORA3 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.